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OBJECTIVES The purpose of this study was to analyze whether long-term treatment with the nonselective
beta-adrenergic blocking agent carvedilol may have beneficial effects in patients with dilated
cardiomyopathy (DCM), who are poor responders in terms of left ventricular (LV) function
and exercise tolerance to chronic treatment with the selective beta-blocker metoprolol.
BACKGROUND Although metoprolol has been proven to be beneficial in the majority of patients with heart
failure, a subset of the remaining patients shows long-term survival without satisfactory
clinical improvement.
METHODS Thirty consecutive DCM patients with persistent LV dysfunction (ejection fraction #40%)
and reduced exercise tolerance (peak oxygen consumption ,25 ml/kg/min) despite chronic
(.1 year) tailored treatment with metoprolol and angiotensin-converting enzyme inhibitors
were enrolled in a 12-month, open-label, parallel trial and were randomized either to continue
on metoprolol (n 5 16, mean dosage 142 6 44 mg/day) or to cross over to maximum
tolerated dosage of carvedilol (n 5 14, mean dosage 74 6 23 mg/day).
RESULTS At 12 months, patients on carvedilol, compared with those continuing on metoprolol, showed
a decrease in LV dimensions (end-diastolic volume 28 6 7 vs. 17 6 6 ml/m2, p 5 0.053;
end-systolic volume 27 6 5 vs. 16 6 4 ml/m2, p 5 0.047), an improvement in LV ejection
fraction (17 6 3% vs. 21 6 2%, p 5 0.045), a reduction in ventricular ectopic beats (212 6
9 vs. 162 6 50 n/h, p 5 0.05) and couplets (20.5 6 0.4 vs. 11.5 6 0.6 n/h, p 5 0.048),
no significant benefit on symptoms and quality of life and a negative effect on peak oxygen
consumption (20.6 6 0.6 vs. 11.3 6 0.5 ml/kg/min, p 5 0.03).
CONCLUSIONS In DCM patients who were poor responders to chronic metoprolol, carvedilol treatment was
associated with favorable effects on LV systolic function and remodeling as well as on
ventricular arrhythmias, whereas it had a negative effect on peak oxygen consumption. (J Am
Coll Cardiol 1999;33:1926–34) © 1999 by the American College of Cardiology
The progression of heart failure is mainly related to neuro-
hormonal activation, including renin–angiotensin–
aldosterone and sympathetic nervous systems (1).
It is well known that angiotensin-converting enzyme
(ACE) inhibitors have beneficial effects on left ventricu-
lar (LV) remodeling (2) and reduce morbidity and
mortality in patients with heart failure (3). Moreover, in
the recent years several convincing demonstrations re-
garding the benefits of adrenergic antagonists have been
provided (4 – 6). In fact, after a transient negative phar-
macologic response (7), a time-dependent partial rever-
sion of LV dysfunction and remodeling was demon-
strated (8).
Metoprolol, a second-generation beta1-selective blocking
agent, significantly improved symptoms and quality of life,
LV function and hemodynamics in most patients with
idiopathic dilated cardiomyopathy (DCM) (4,9). However,
a subset of the others showed persistent LV dysfunction
despite tailored medical therapy (9).
Carvedilol, a third-generation beta1-, beta2- and alpha1-
blocker with ancillary properties was demonstrated as being
able to extend the favorable effects of selective beta-blocking
agents to produce a significant reduction of mortality in
heart failure (5). Thus, exerting a more complete antago-
nism on sympathetic activation than metoprolol (10), carve-
dilol could have additional benefits on symptoms and LV
function in heart failure.
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The present study was designed to evaluate the additional
beneficial effects of carvedilol in highly selected patients
with DCM with persistent LV dysfunction and reduced
exercise tolerance despite long-term tailored treatment with
digitalis, ACE inhibitors and the beta1-selective blocker
metoprolol.
METHODS
Study design. We performed a 12-month, open-label,
parallel, randomized and controlled trial on clinically stable
DCM patients who were poor responders to chronic treat-
ment with metoprolol in addition to conventional therapy
on the basis of a persistent moderate to severe LV dysfunc-
tion and reduced exercise tolerance.
Patients were randomized to continue either on meto-
prolol or to cross over to carvedilol on a 1:1 basis. End
points included: 1) the completion of the study, 2) worsen-
ing heart failure not controlled by the adjustment of medical
therapy, 3) life-threatening ventricular arrhythmias, 4) the
inclusion on a waiting list for cardiac transplant and 5)
death.
The primary objectives were to evaluate the additional
beneficial effects of long-term carvedilol treatment on LV
function and remodeling. The secondary objectives were to
assess the effects of carvedilol on symptoms, quality of life,
exercise tolerance and ventricular arrhythmias.
Study population. From April 1994 to December 1995,
from among 154 DCM patients referred to, and followed
up in, our Heart Failure Clinics (Department of Cardiology,
Trieste, Italy), 30 patients were consecutively selected on
the basis of the following inclusion criteria: 1) chronic (.12
months) tailored metoprolol plus conventional heart failure
therapy (ACE inhibitors, digitalis, diuretics), 2) persistent
moderate to severe LV dysfunction (LV ejection fraction
[EF] by echocardiography or radionuclide angiography
#40%) and 3) reduced exercise tolerance (peak oxygen
consumption [VO2] ,25 ml/kg/min).
Patients were excluded if they had: 1) clinically unstable
heart failure or changes of heart failure treatment in the last
three months before randomization, 2) inclusion on waiting
list for cardiac transplant, 3) sustained or symptomatic
ventricular tachycardia that had not been adequately con-
trolled by amiodarone therapy, 4) atrial flutter or fibrillation
or other sustained supraventricular arrhythmias or 5)
second- or third-degree atrioventricular block, unless the
patients had been equipped with a permanent pacemaker.
Informed consent was obtained from all patients.
In all patients, previous DCM diagnosis had been based
on World Health Organization criteria (11). In particular,
the presence of significant coronary artery disease (stenosis
.50% of at least one epicardial vessel) had been excluded by
coronary angiography and active myocarditis by endomyo-
cardial biopsy, according to the “Dallas criteria” (12).
After careful clinical stabilization with tailored dosages of
ACE inhibitors (mainly enalapril), digitalis and diuretics, all
selected patients had tolerated increasing dosages of meto-
prolol, starting from 5 mg b.i.d. up to 200 mg a day with a
target rest heart rate of 60 beats/min (range 50 to 70) or
systolic blood pressure of 100 mm Hg (range 90 to 110) (9).
The daily dosage of ACE inhibitors was converted to
captopril equivalent doses multiplying by the following
correction factors: enalapril 3.75, captopril 1.0, lisinopril
3.75, quinapril 1.88 and ramipril 7.5 (13).
All cases had been followed up after diagnosis by serial
noninvasive evaluations and according to the patient’s clin-
ical needs for at least 12 months (mean 34 6 4 months)
before randomization.
Randomization, open challenge, up-titration and main-
tenance period. Sixteen of the 30 patients enrolled were
randomized to continue on the same dosage of metoprolol,
and 14 to cross over to carvedilol. After careful evaluation of
heart failure stability, the transition from metoprolol to
carvedilol was carried out under strict clinical observation in
our Heart Failure Clinics. An open-label challenge was
administered beginning the day after metoprolol withdrawal
(usually 18 h after the last metoprolol administration) and
continuing at 12-h intervals for 3 days. Down-titration of
metoprolol was not required by our study protocol. In 11 out
of 14 patients (79%), treated with $100 mg/day of meto-
prolol and systolic blood pressure .100 mm Hg, the test
dose of carvedilol was 12.5 mg b.i.d, whereas 3 patients
(21%) were initially tested with the usual 6.25 mg b.i.d.
Patients were classified as “not tolerant” if they showed
symptoms or signs of worsening heart failure, hypoperfu-
sion, significant hypotension (defined as systolic blood
pressure ,80 mm Hg), marked sinus bradycardia (defined
as rest heart rate ,40 beats/min) or appearance of advanced
atrioventricular block.
In patients who successfully completed the open-label
challenge, carvedilol was titrated every three days up to the
maximum tolerated dosage, according to the following
scheme: 12.5 mg b.i.d., 12.5 mg t.i.d., 25 mg b.i.d., 25 mg
t.i.d., 50 mg b.i.d. The three patients who initially tolerated
a carvedilol test dose of 6.25 mg b.i.d. were titrated up
according the same scheme but starting from 6.25 mg b.i.d.
followed by 6.25 mg t.i.d. for three days.
In the same way as metoprolol, the dosage of carvedilol
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could be modified after the end of titration to obtain a
comparable degree of beta blockade with a target rest heart
rate of 60 beats/min (range 50 to 70) or systolic blood
pressure of 100 mm Hg (range 90 to 110).
Study protocol. The severity of heart failure symptoms was
assessed by the New York Heart Association (NYHA)
functional class, Heart Failure Score (14) and the Minne-
sota “Living With Heart Failure” Questionnaire (15). Rou-
tine clinical laboratory tests (including complete blood
count, chemistry panel and urinalysis) were performed at
baseline and serially repeated throughout the study period.
All patients underwent chest X ray, electrocardiogram,
ambulatory 24-h Holter monitoring and echocardiogram at
baseline, 6 and 12 months.
Conventional M-mode, two-dimensional and Doppler
echocardiographic variables (16,17) were measured in all
patients. Left ventricular end-diastolic (EDV) and end-
systolic (ESV) volumes were calculated from the apical
four-chamber view using the ellipsoid, single-plane formula.
All measurements were obtained in sinus rhythm as a mean
of three consecutive beats. Chamber diameters and volumes
were normalized for body surface areas. In two patients (one
randomized to metoprolol, one to carvedilol), in whom the
echocardiograms were not adequate for quantitative evalu-
ations, LVEF was assessed by radionuclide angiography.
Echocardiographic studies were reviewed by two inde-
pendent investigators. Reproducibility of two-dimensional
and Doppler echocardiographic data in our laboratory were
previously assessed in 25 patients with DCM: no rater effect
was demonstrated and the observations were consistent
across measurements (17). Intraobserver and interobserver
variability (mean 6 SEM) were respectively 7 6 1 and 2 6
1% for LVEF, 9 6 4 and 4 6 4 ml/m2 for LVEDV, 7 6
2 and 3 6 4 ml/m2 for LVESV and 0 6 5 and 8 6 3 ms for
deceleration time of mitral E wave.
Bicycle maximal exercise tests were performed with mea-
surements of peak VO2 at baseline and after 12 months.
The maximal protocol consisted of 1 min of free pedaling,
followed by 10-W/min incremental exercise to exhaustion.
Dyspnea or fatigue were the required end points to stop the
exercise. Expired gas analysis was made by an infrared and
paramagnetic gas analyzer using the breath by breath
method. Peak VO2 was defined as the average oxygen
consumption during the last minute of maximal exercise.
Anaerobic threshold was detected by the V-slope method.
The cardiopulmonary exercise test was performed using an
instrument which met the standards of the European
Respiratory Society Task Force (18). Furthermore, all pa-
tients underwent a spirometry and a single-breath carbon
monoxide diffusing capacity according to the American
Thoracic Society statements (19,20).
A submaximal exercise test was then performed using the
maximal one to determine the appropriate work level.
During the submaximal protocol patients exercised at 10
W/min, with incremental steps up to 75% of baseline
maximal workload, and then continued to exhaustion. Six-
and 12-month submaximal tests were performed at the
same workload of the baseline evaluation.
Clinical, echocardiographic and cardiopulmonary evalua-
tions were performed by different investigators. Echocardio-
graphic and cardiopulmonary operators were blind to pa-
tient allocation.
Statistical analysis. Data are expressed as mean 6 SEM or
percentages. All differences were tested using a model-based
approach. This was due to the need to adjust for some
potentially confounding factors, for instance mild hyperten-
sion, length of the disease and therapy with amiodarone.
New York Heart Association functional class of patients at
randomization was not considered as a confounder because
of the very few patients in class III would have led the model
to being highly unstable.
Parallel sample-like tests were based on quasi-likelihood
models with link and variance function specification tailored
to the form of the response (identity link and constant
variance for continuous variables and logit link and binomial
variance for dichotomous variables) (21). Tests for categor-
ical ordered responses were based on a proportional odds
model. Paired samples-like tests were based on the same
models but fitted using the generalized estimating equations
(22) approach with an autoregressive order one working
correlation structure.
To interpret the data properly, all p values #0.25 were
specified. A two-tailed p value ,0.05 was considered
significant.
Data were stored in the Heart-Muscle Disease Registry
using Oracle (23) and the statistical analyses were carried
out using S-plus (24).
RESULTS
Patient characteristics. The 30 patients with DCM en-
rolled in the present study were identified as poor respond-
ers to chronic metoprolol treatment on the basis of persis-
tent moderate to severe LV dysfunction and reduced
exercise tolerance.
Compared with data at diagnosis before the beginning of
metoprolol treatment, patients showed at randomization a
predictable lower rest heart rate (60 6 1 vs. 86 6 2
beats/min, p , 0.001) and an improvement of symptomatic
status (NYHA class I/II/III 8/19/3 vs. 4/19/7, p 5 0.02;
Heart Failure Score 1.1 6 0.2 vs. 1.8 6 0.3, p 5 0.02;
exercise tolerance 788 6 36 vs. 618 6 37 s, p , 0.001)
associated with a not clinically relevant effect on LV
function (EF 29 6 1 vs. 25 6 1%, p 5 0.007) and
remodeling (EDV: 121 6 7 vs. 133 6 7 ml/m2, p 5 0.15).
Thus, at randomization, patients were characterized by
mildly symptomatic chronic heart failure with a moderate to
severe LV dysfunction despite long-term metoprolol treat-
ment. In all patients concomitant therapy consisted of
digitalis and maximum tolerated dosages of ACE inhibitors
(captopril equivalent dosage 112 mg/day); 23 patients (77%)
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were taking diuretics (furosemide: 9 patients; thiazides: 14
patients) and 3 patients (10%) with complex symptomatic
ventricular arrhythmias were receiving amiodarone.
Sixteen out of 30 patients were randomized to continue
on the same metoprolol dosage, and 14 to cross over to
carvedilol titrated up to the maximum tolerated dosage.
There were no significant differences in baseline clinical
findings between the two groups (Table 1). Metoprolol and
carvedilol patients did not differ in concomitant therapy at
baseline or during the study period.
Drug tolerability and degree of beta blockade. Beta-
blocker therapy was well tolerated in all patients. During
titration of carvedilol, mildly symptomatic hypotension
rarely required temporary adjustment of diuretics or ACE
inhibitors.
Throughout the course of the study, 24-h Holter moni-
toring documented a nocturnal worsening of atrioventricu-
lar conduction (first or second atrioventricular block) in four
carvedilol patients (29%); the maintenance dosage of carve-
dilol was slightly reduced in two of these patients (14%),
who had a nocturnal heart rate ,40 beats/min. One
carvedilol patient (7%) showed episodes of symptomatic
hypotension, and two others (14%) complained of fatigue.
No other side effect was documented.
No patient reached any predefined end point, and all of
them completed the 12-month study period. One patient
randomized to carvedilol was hospitalized because of symp-
tomatic paroxysmal atrial fibrillation.
A similar degree of beta blockade, expressed by 12-month
heart rate at rest (respectively 61 6 3 vs. 60 6 2 beats/min,
p 5 NS), 24-h Holter monitoring (68 6 3 vs. 69 6 2
beats/min, p 5 NS) and peak exercise (115 6 5 vs. 116 6
7 beats/min, p 5 NS), was obtained by carvedilol and
metoprolol at a dosage ratio of approximately 1:2 (respec-
tively 74 6 6 vs. 142 6 11 mg/day). Systolic blood pressure
did not significantly change between the two groups, with a
tendency to a mild decrease in patients on carvedilol (21 6
3 mm Hg at 6 months, 23 6 3 mm Hg at 12 months; p 5
NS) and to a mild increase in those on metoprolol (15 6
3 mm Hg at 6 months, 12 6 4 mm Hg at 12 months; p 5
NS).
Effects on LV function and remodeling. Compared with
the absence of significant changes in those continuing on
metoprolol, patients on carvedilol showed a significant time-
dependent improvement of LVEF (at 6 months: 12.5 6
2.5%, p 5 0.20 vs. baseline; at 12 months: 17 6 3%, p 5
0.033 vs. baseline) (Fig. 1) (Table 2). Overall, at 12 months
LVEF improved by 7.8% (95% confidence interval [CI] 13%
to 112%) in the carvedilol group as compared with the
metoprolol group. Nine patients on carvedilol showed an
increase of LVEF $5%, with a remarkable improvement
$10% in five of them (mean 117%, range 112% to 128%)
(Table 3). Notably, changes in LVEF were not related to
the duration of metoprolol treatment before randomization
both in the carvedilol group (metoprolol therapy #24
months [n 5 6] vs. .24 months [n 5 8]: 15.9 6 4.7 vs.
17.3 6 3.7%, p 5 NS) and in the metoprolol group
(metoprolol therapy #24 months [n 5 7], vs. .24 months
[n 5 9]: 10.9 6 3.2 vs. 21.7 6 2.4%, p 5 NS).
Carvedilol and metoprolol showed a different effect at 12
months on LVEDV (respectively 28 6 7 vs. 17 6 6
ml/m2, p 5 0.053) and LVESV (27 6 5 vs 16 6 4 ml/m2,
Table 1. Baseline Characteristics of 30 Dilated Cardiomyopathy Patients With Persistent LV Dysfunction Despite Chronic Optimal
Treatment Including Angiotensin-Converting Enzyme Inhibitors and Metoprolol
All Population
(n 5 30)
Metoprolol
(n 5 16)
Carvedilol
(n 5 14) p
Duration of heart failure symptoms (mo) 60 6 10 70 6 16 50 6 11 0.13
Duration of metoprolol therapy (mo) 34 6 4 40 6 8 29 6 4 0.11
Mild hypertension (n, %) 6 (20) 4 (25) 2 (14) 0.15
NYHA functional class (I/II/III) (n) 8/19/3 3/10/3 5/9/0 0.17
Blood pressure (mm Hg) 121 6 2/75 6 2 118 6 3/73 6 3 124 6 3/78 6 3 0.14/0.13
Resting heart rate (beats/min) 60 6 1 59 6 2 60 6 2 NS
Left bundle branch block (n, %) 19 (63) 12 (73) 7 (50) 0.21
LV end-diastolic diameter (mm/m2) 38 6 1 38 6 1 37 6 1 0.17
LV end-diastolic volume (ml/m2) 121 6 7 126 6 12 115 6 9 0.16
LV ejection fraction (%) 29 6 1 29 6 2 29 6 2 NS
Mitral regurgitation (0–4) 1.3 6 0.1 1.4 6 0.2 1.2 6 0.2 0.18
E-wave deceleration time (ms) 232 6 14 252 6 16 210 6 24 0.07
Ventricular ectopic beats (n/h) 68 6 23 67 6 40 68 6 19 NS
Ventricular couplets (n/h) 1.2 6 0.5 0.1 6 0.05 2.4 6 1.1 NS
Nonsustained ventricular tachycardia (n/h) 0.05 6 0.02 0.01 6 0.01 0.1 6 0.06 NS
Maximal exercise tolerance (s) 788 6 36 776 6 58 802 6 41 NS
Maximal heart rate (beats/min) 126 6 3 121 6 5 131 6 3 0.09
Peak VO2 (ml/kg/min) 18 6 1 17 6 1 18 6 1 0.18
Submaximal exercise tolerance (s) 862 6 65 906 6 119 815 6 46 0.13
LV 5 left ventricular; NYHA 5 New York Heart Association; VO2 5 volume of oxygen consumption.
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p 5 0.047) (Fig. 2). There was therefore an overall
difference of 15 ml/m2 (95% CI 23 to 227 ml/m2) in
LVEDV and of 13 ml/m2 (95% CI 24 to 222 ml/m2) in
LVESV between the carvedilol and metoprolol groups.
Effects on symptoms, quality of life and exercise toler-
ance. The NYHA class, the Heart Failure Score, the
Minnesota “Living With Heart Failure” Questionnaire and
submaximal exercise tolerance did not significantly change
between the two groups (Table 4).
At 12 months, the maximal exercise tolerance was slightly
reduced in both groups but to a greater, although not
significant, extent in carvedilol (247 6 31 vs. 214 6 16 s,
p 5 0.19). Notably, seven patients (54%) treated with
carvedilol, compared with one on metoprolol, worsened
their maximal exercise time by at least 2 min (p 5 0.003)
(Table 3). Moreover, the two study drugs showed a different
effect on peak VO2 at 12 months (20.6 6 0.6 vs. 11.3 6
0.5 ml/kg/min, p 5 0.03). Overall, peak VO2 was reduced
by 1.9 ml/kg/min (95% CI 20.9 to 22.9) in the carvedilol
compared with the metoprolol group. Compared with
metoprolol, at 12 months the negative effect of carvedilol on
exercise capacity was associated with a more evident, al-
though not significant, reduction of maximum heart rate
(216 6 5 vs. 27 6 4 beats/min, p 5 0.13).
Effects on ventricular arrhythmias. Compared with
metoprolol patients, those on carvedilol showed a positive
effect on ventricular ectopic beats (212 6 9 vs. 162 6 50
n/h, p 5 0.05) and couplets (20.5 6 0.4 vs. 11.5 6 0.6
n/h, p 5 0.048) but not a significant effect on episodes of
nonsustained ventricular tachycardia (Table 4). Similarly,
the distribution of patients with an increase or a reduction of
ventricular extrasystoles ($30/h) or couplets was signifi-
cantly different in favor of carvedilol (Table 3).
DISCUSSION
Previous data reported a progressive and sustained improve-
ment of heart failure symptoms and LV function (4–9) in
most DCM patients treated with metoprolol. Nevertheless,
a consistent proportion of remaining patients survived with
a persistent moderate to severe LV dysfunction, even
though an improvement of symptoms was often detectable.
During long-term follow-up, these patients may be at
higher risk of worsening heart failure, heart transplantation
or death (25).
Carvedilol, a third-generation mildly beta1-selective an-
tagonist (26,27) with a vasodilator action related to alpha1-
receptor blockade (26–29) and potentially relevant antiox-
idant (30) and antiproliferative (31) properties, might
produce different and more favorable clinical effects in
chronic heart failure compared with the second-generation
beta1-selective antagonist metoprolol.
We tested this hypothesis in strictly selected DCM
patients characterized by stable heart failure symptoms but
no clinically relevant improvement of LV function despite
tailored long-term treatment (three years on average) with
ACE inhibitors, digitalis and metoprolol. Thus, we ran-
domized in our open-label, parallel trial, 30 consecutive
patients either to continue on metoprolol or to cross over to
carvedilol for 12 months.
At the end of the study period, compared with metopro-
lol, carvedilol was associated with a positive effect on LV
Figure 1. Time-dependent improvement of left ventricular ejec-
tion fraction (LVEF) with carvedilol (n 5 14, black circles) or
metoprolol (n 5 16, open circles) in dilated cardiomyopathy
patients with persistent left ventricular dysfunction despite chronic
optimum treatment including angiotensin-converting enzyme in-
hibitors and metoprolol. *p 5 0.033, 12 months vs. baseline
carvedilol; †p 5 0.046, D 12 months carvedilol vs. metoprolol.
Table 2. Effect of Carvedilol Versus Metoprolol on LV Function and Remodeling in 30 Dilated Cardiomyopathy Patients
Metoprolol (n 5 16, 142 6 11 mg/day) Carvedilol (n 5 14, 74 6 6 mg/dl)
Baseline
D 6
Months
D 12
Months Baseline
D 6
Months
D 12
Months
LV end-diastolic diameter (mm/m2) 38 6 1.3 20.6 6 0.6 20.5 6 0.7 37 6 1.4 20.6 6 0.9 20.6 6 0.9
LV end-diastolic volume (ml/m2) 126 6 12 111 6 6* 17 6 6* 115 6 9 24 6 5* 28 6 7*
LV end-systolic volume (ml/m2) 91 6 10 19 6 4† 16 6 4† 80 6 7 22 6 5† 27 6 5†
LV ejection fraction (%) 29 6 2 20.3 6 2 20.8 6 2† 29 6 2 12.5 6 2.5 17 6 3†‡
E-wave deceleration time (ms) 252 6 16 219 6 19 220 6 21 210 6 24 33 6 32 15 6 34
E/A ratio 1 6 0.1 20.04 6 0.1 20.1 6 0.1 1.2 6 0.2 20.1 6 0.2 20.04 6 0.2
Mitral regurgitation (0–4) 1.4 6 0.2 10.1 6 0.2 10.25 6 0.2 1.2 6 0.2 20.1 6 0.2 0 6 0.2
*p , 0.10, D 6 or D 12 months carvedilol vs. metoprolol; †p , 0.05, D 6 or D 12 months carvedilol vs. metoprolol; ‡p , 0.05, D 12 months vs. baseline carvedilol or metoprolol.
LV 5 left ventricular.
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systolic function and remodeling, and a reduction of ven-
tricular arrhythmias. Conversely, a neutral effect on heart
failure symptoms and a worsening of maximal exercise
capacity were observed in patients on carvedilol.
Drug tolerability and degree of beta blockade. Although
down-titration has been shown to reduce the rebound
effects of beta blockade discontinuation (32), nevertheless
the withdrawal of metoprolol may lead to worsening heart
failure and arrhythmias (33,34). So, to avoid leaving patients
without beta-blocker treatment, we administered carvedilol
under strict clinical observation beginning the day after
metoprolol withdrawal. This strategy was well tolerated in
all cases without worsening heart failure. Furthermore, the
long-term treatment with tailored dosages of metoprolol,
combined with the optimum clinical stability of the patients
enrolled, favored the good tolerability of a higher than usual
test dose of carvedilol (12.5 mg b.i.d.), rapidly titrated (every
3 days) up to the maximum tolerated dosages.
Our experience would suggest that, in clinically stable
patients with LV dysfunction, the transition from metopro-
lol to carvedilol is a practical and safe method.
As expected, in view of the higher affinity of carvedilol for
beta receptors (26) and in accordance with previous trials
(4,5,35,36), a comparable degree of beta blockade was
obtained in our study at a dosage ratio of carvedilol to
metoprolol of 1:2.
Effects on LV function and remodeling. The improve-
ment of LV function with metoprolol in heart failure was
related to baseline heart rate (9) and to its changes with
treatment (37,38). The consequent decrease of myocardial
Table 3. Effect of Carvedilol Versus Metoprolol at 12 Months on Categorical Measures of
Clinical Status, LV Function and Ventricular Arrhythmias in 30 Dilated
Cardiomyopathy Patients
Parameters and Changes
Metoprolol
(n 5 16, 142 6 11 mg/day)
Carvedilol
(n 5 14, 74 6 6 mg/day) p
NYHA functional class NS
Improved $1 class 1 (6%) 4 (28.5%)
Unchanged 13 (82%) 9 (64.5%)
Worsened $1 class 2 (12%) 1 (7%)
Maximal exercise tolerance* 0.003
Increased $2 min 0 2 (15%)
Unchanged 13 (87%) 4 (31%)
Decreased $2 min 2 (13%) 7 (54%)
LV ejection fraction 0.09
Increased
$10% 2 (13%) 5 (36%)
$5 and ,10% 2 (13%) 4 (29%)
Unchanged 9 (56%) 2 (14%)
Decreased
$5 and ,10% 1 (6) 3 (22%)
$10% 2 (13%) 0
Ventricular ectopic beats 0.03
Increased $30/h 8 (50%) 2 (14%)
Unchanged 6 (38%) 7 (50%)
Decreased $30/h 2 (12%) 5 (36%)
Ventricular couplets 0.01
Increased 10 (63%) 4 (29%)
Unchanged 4 (25%) 2 (14%)
Decreased 2 (12%) 8 (57%)
*Maximal exercise test was not performed in two patients (one on metoprolol, one on carvedilol). LV 5 left ventricular;
NYHA 5 New York Heart Association.
Figure 2. Effects of 12-month carvedilol (n 5 14, black bars) or
metoprolol (n 5 16, open bars) treatment on left ventricular (LV)
remodeling in dilated cardiomyopathy patients with persistent LV
dysfunction despite chronic optimum treatment including
angiotensin-converting enzyme inhibitors and metoprolol. *p 5
0.053, D 12 months carvedilol vs. metoprolol; †p 5 0.047, D 12
months carvedilol vs. metoprolol. LVEDV 5 LV end-diastolic
volume; LVESV 5 LV end-systolic volume.
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energy consumption and the modification in force–
frequency relation are undoubtedly part of the mechanisms
of improvement with beta-blockers (39). On the contrary,
in this study the response to carvedilol in the absence of any
significant further change in heart rate suggests that there
are other contributory factors.
A relevant effect of alpha blockade seems unlikely, since a
previous trial showed the development of tolerance to alpha
blockade after a few months of therapy (35). Otherwise, the
vasodilator action of carvedilol could improve the short-
term low tolerability of nonselective beta-blockers in more
compromised patients (27,40). In fact, previous trials
showed an acute significant reduction of LV filling pressure
and systemic blood pressure in carvedilol-treated patients
compared with those treated with metoprolol (35,41,42).
Gilbert et al. (10) recently reported that carvedilol and
metoprolol significantly differ in their effects on adrenergic
activity and on cardiac beta-adrenergic receptors. In that
study, metoprolol was associated with an increased level of
central venous norepinephrine with no apparent effect on
transmyocardial balance and with an up-regulation of beta1-
receptor subpopulation, down-regulated in the failing hu-
man heart. Conversely, carvedilol reduced two indexes of
cardiac adrenergic activity, central venous norepinephrine
and transmyocardial norepinephrine balance, without af-
fecting systemic norepinephrine levels, and showed no effect
on beta-adrenergic receptor density, although it was asso-
ciated with effects on hemodynamics, LV function and heart
failure symptoms at least as favorable as those produced by
metoprolol.
Compared with the expected lack of further significant
changes in patients randomized to continue on metoprolol,
patients who crossed over to carvedilol showed a significant
effect on LV systolic function with a net increase in LVEF
of 7.8% after 12 months and, impressively, an improvement
of $10% in five of them (35.7%).
These data seem to agree with the results of previous 4-
to 6-month placebo-controlled trials showing a tendency to
a greater improvement of LVEF on carvedilol (19/111%)
(10,35,36,43), with respect to metoprolol (16%) (4). In our
study, the effect of carvedilol on LVEF was favored by a
longer study period but seems particularly relevant consid-
ering the strictly selected characteristics of our DCM
patients.
Notably, the improvement of LV systolic function in
patients treated with carvedilol was associated with a slight
decrease of LV volumes compared with those continuing on
metoprolol. It is well known that ACE inhibitors have
beneficial effects on ventricular remodeling by slowing the
progression of chamber dilation in patients with myocardial
infarction and LV dysfunction (2). More recently, Doughty
et al. (44) provided evidence of the benefits of carvedilol in
addition to ACE inhibitors on LV remodeling in ischemic
cardiomyopathy patients. Our data on DCM patients are
consistent with those of Doughty et al. (44) and suggest the
possibility that carvedilol, compared with metoprolol, could
influence a partial reversion of ventricular remodeling more
efficiently, as also hypothesized by Eichhorn and Bristow
(8).
Effects on symptoms, quality of life and exercise toler-
ance. In most studies (35,36,43,45) both carvedilol and
metoprolol showed a favorable effect on symptoms and
quality of life, with some advantages for carvedilol (10). It is
conceivable that the mild functional impairment of our
study population at enrollment could have reduced the
margins of improvement with treatment.
Conversely, beta-adrenergic receptor down-regulation of
failing heart appears to contribute to the decline in maximal
exercise response (46). In this case, it is interesting to note
that metoprolol, which has been shown to up-regulate beta1
receptors, was demonstrated as improving maximal exercise
response (4) in contrast to carvedilol (2,35,36,45). In our
study, the unfavorable effect of carvedilol on maximal
exercise capacity was associated to a greater, but not signif-
icant, decrease of maximum heart rate in comparison with
Table 4. Effect of Carvedilol Versus Metoprolol on Symptoms, Quality of Life, Exercise Tolerance and Arrhythmias in 30 Dilated
Cardiomyopathy Patients
Metoprolol (n 5 16, 142 6 11 mg/day) Carvedilol (n 5 14, 74 6 6 mg/day)
Baseline D 6 Months D 12 Months Baseline D 6 Months D 12 Months
NYHA functional class (I/II/III) (n) 3/10/3 5/9/2 5/9/2 5/9/0 8/6/0 10/3/1
Heart Failure Score (0–13) 1.2 6 0.3 10.1 6 0.1 10.25 6 0.2 1 6 0.2 20.1 6 0.1 20.2 6 0.3
Minnesota Questionnaire (0–105) 16 6 3 20.6 6 1 21.2 6 2.7 15 6 3 22.3 6 2 21.6 6 3
Maximal exercise tolerance (s) 776 6 58 214 6 16 802 6 41 247 6 31
Anaerobic threshold (ml/kg/min) 11 6 0.6 20.5 6 0.4 9 6 0.4 20.8 6 0.4
Peak VO2 (ml/kg/min) 17 6 1 11.3 6 0.5* 18 6 0.8 20.6 6 0.6*
Submaximal exercise tolerance (s) 906 6 119 124 6 82 158 6 86 815 6 46 199 6 50 178 6 79
Ventricular ectopic beats (n/h) 67 6 40 18 6 25 162 6 50* 68 6 19 26.9 6 7 212 6 9*
Ventricular couplets (n/h) 0.2 6 0.05 10.6 6 0.2* 11.5 6 0.6* 2.4 6 1.1 20.2 6 0.2* 20.5 6 0.4*
Nonsustained ventricular
tachycardia (n/h)
0.01 6 0.01 10.03 6 0.01 10.03 6 0.01 0.1 6 0.06 20.02 6 0.02 20.02 6 0.03
*p , 0.05, D 6 or D 12 months carvedilol vs. metoprolol. NYHA 5 New York Heart Association; VO2 5 volume of oxygen consumption.
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metoprolol. Nevertheless, the blunting of maximal vasodi-
lating response mediated by peripheral beta2 antagonism
could contribute to explaining the negative effect of carve-
dilol on maximal exercise.
Effects on ventricular arrhythmias. A previous random-
ized trial in patients with DCM showed a significant effect
of carvedilol in reducing ventricular arrhythmias (36). Sim-
ilarly, our patients treated with carvedilol, in comparison
with those on metoprolol, showed an additional beneficial
effect on the reduction of ventricular arrhythmias evaluated
by 24-h Holter monitoring. Whereas previous trials with
beta1-selective antagonists in DCM failed to show a reduc-
tion of arrhythmic deaths (4,47), our data seem to be in
accordance with the possibility of a significant prevention of
sudden cardiac death with carvedilol (5).
Study limitations. A recognized limitation of the present
study is that it was open-label. This lack of blinding is
particularly relevant for more subjective parameters. For this
reason we avoided considering symptoms as the selection
criteria or NYHA functional class evaluation as a primary
objective of the present study. However, it must be pointed
out that all instrument readings were done by blinded
operators. Thus the potential impact of investigator subjec-
tivity was greatly limited.
Another limitation is the relatively small number of study
patients. Yet, it deserves to be pointed out how enrollment
was strongly affected by the strict selection criteria, requiring
DCM patients with stable heart failure who were poor
responders in terms of LV systolic function and reduced
exercise tolerance to optimum medical therapy including
long-term metoprolol. Even though we are aware that a
larger number of subjects could have improved the power of
our results, nevertheless the size of our study population did
not hinder the identification of significant differences be-
tween carvedilol and metoprolol patients using a conserva-
tive statistical approach.
Finally, although the carvedilol and metoprolol groups
did not significantly differ in their baseline characteristics,
we recognize that some randomization imbalances may
exist. In particular, being aware that more chronic patients
might be sicker, we performed all our analyses considering
the duration of heart failure as a confounder. These consid-
erations make us confident about our conclusions.
The results of this study might not be applicable to
patients with ischemic cardiomyopathy. However, previous
trials (4–6) suggest the possibility of an additive effect of
carvedilol compared with metoprolol also in ischemic pa-
tients.
Conclusions. The results of the present study on a selected
population of DCM patients, who were poor responders to
long-term optimum treatment for heart failure including
metoprolol, suggest a benefit of carvedilol on LV function,
remodeling and arrhythmias, and a negative effect on peak
exercise compared with metoprolol.
These effects may be secondary to a greater cardioprotec-
tion from sympathetic activation (10) due to the nonselec-
tive blockade of adrenergic receptors, lowering cardiac
adrenergic activity and not sensitizing to adrenergic stimu-
lation the down-regulated beta1-adrenergic pathway.
Whether the different effects of these two beta-blockers
on relevant prognostic markers such as LV function and
arrhythmias could influence cardiac mortality will be ana-
lyzed by the ongoing multicenter Carvedilol or Metoprolol
European Trial (48).
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